- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer
Experts discuss oral SERDs in the pipeline, clinical pathways for treatment of breast cancer, and strategies to help ensure patients have access to treatment. The participants also describe diverse agents in development, including their toxicity profiles.
EP: 1.Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer
EP: 2.Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer
EP: 3.Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles
EP: 4.ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer
EP: 5.Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer
EP: 6.Elacestrant: Treatment Considerations, Including Dosing and Compliance
EP: 7.Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life
EP: 8.Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer
EP: 9.Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer
EP: 10.Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer
EP: 11.The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer
EP: 12.Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer
EP: 13.Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer
This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.
Mardones addresses strategies to reduce barriers to medication access, with Callahan emphasizing the role of clinical pathways in streamlining ESR1 mutation testing documentation. Vidal discusses oral selective estrogen receptor degraders (SERDs) in development, highlighting differences in toxicity profiles among agents and expressing anticipation for these options in clinical practice. Gradishar explores the evolving landscape of new agents. The discussion emphasizes the need for differentiation and efficacy data among emerging drugs, which promise an exciting era with expanded treatment options for patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) breast cancer. Concluding the peer exchange, each expert shares their final thoughts, celebrating the current and upcoming advancements in ER+/HER– breast cancer therapeutics, focusing on their efficacy, tolerability, and potential to improve patient outcomes and quality of life. Stay informed about the evolving landscape of breast cancer treatments and explore the promising future of tailored therapies.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
